Litigation Details for Keryx Biopharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

✉ Email this page to a colleague

Keryx Biopharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Docket	⤷ Start Trial	Date Filed	2018-12-19
Court	District Court, D. Delaware	Date Terminated	2020-05-04
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	7,767,851; 8,093,423; 8,299,298; 8,338,642; 8,609,896; 8,754,257; 8,754,258; 8,846,976; 8,901,349; 9,050,316; 9,328,133; 9,387,191; 9,757,416
Link to Docket	External link to docket

Small Molecule Drugs cited in Keryx Biopharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.

The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .

Details for Keryx Biopharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2018-12-19				External link to document
2018-12-18	1		United States Patent Nos. 7,767,851 (the “’851 patent”); 8,093,423 (the “’423 patent”); 8,299,298 (the…(the “’298 patent”); 8,338,642 (the “’642 patent”); 8,609,896 (the “’896 patent”); 8,754,257 (the “’257…’257 patent”); 8,754,258 (the “’258 patent”); 8,846,976 (the “’976 patent”); 8,901,349 (the “’349 patent…25 PageID #: 2 patent”); 9,328,133 (the “’133 patent”); 9,387,191 (the “’191 patent”); and 9,757,416… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C	External link to document
2018-12-18	17	Complaint - Amended	United States Patent Nos. 7,767,851 (the “’851 patent”); 8,093,423 (the “’423 patent”); 8,299,298 (the…(the “’298 patent”); 8,338,642 (the “’642 patent”); 8,609,896 (the “’896 patent”); 8,754,257 (the “’257…’257 patent”); 8,754,258 (the “’258 patent”); 8,846,976 (the “’976 patent”); 8,901,349 (the “’349 patent…9,050,316 (the “’316 patent”); 9,328,133 (the “’133 patent”); and 9,757,416 (the “’416 patent”) (collectively… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation summary and analysis for: Keryx Biopharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Last updated: July 1, 2026

Keryx Biopharmaceuticals v. Teva (1:18-cv-02012): Litigation Summary, Patent Issues, and Generic Launch Impact

Executive summary: The case Keryx Biopharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-02012 is a U.S. patent infringement matter tied to Teva’s effort to market a generic version of Keryx’s product portfolio. The litigation posture and remedies hinge on (i) which patents were asserted, (ii) the paragraph IV framework for the relevant ANDA, and (iii) whether the asserted claims cover product composition, formulation, or method-of-use. This summary and analysis tracks the infringement and defenses at the issue level and translates them into generic launch and regulatory risk.

No complete case-specific filing details, asserted patent list, claim construction outcomes, or final judgment terms are present in the provided prompt. Under the constraints, a complete, accurate litigation summary cannot be produced.